Imidlertid vil den foreslåede nye model først have prædiktiv værdi, når den er fuldt valideret og er påvist at kunne skelne mellem de lots af HBVAXPRO, der har fremkaldt høj hhv. lav immunrespons under de kliniske forsøg.
Notwithstanding, the new proposed model will have only predictive value once it has been fully validated and has shown to be able to discriminate batches of HBVAXPRO that have elicited a high vs. a low immune response during clinical trials.